PTJ
MRNS

Paul Tudor Jones’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Paul Tudor Jones’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-9,002
Closed -$103K – 1308
2018
Q4 		$103K Buy
+9,002
New +$182K ﹤0.01% 925

Other funds holding MRNS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Paul Tudor Jones's MRNS Position: Q1 2019 in Review

Paul Tudor Jones sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2019, closing a stake of 9,002 shares — an estimated $103K sold.

Paul Tudor Jones first reported a position in MRNS in Q4 2018 and held it in 1 quarter. The position peaked at $103K in Q4 2018. 81 funds tracked by Wall St. Rank hold MRNS as of Q1 2019.

  • Paul Tudor Jones reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2019 after selling out during the quarter.
  • Paul Tudor Jones sold 9,002 Marinus Pharmaceuticals, Inc shares in Q1 2019, an estimated $103K.
  • Paul Tudor Jones first reported a position in Marinus Pharmaceuticals, Inc in Q4 2018 and held it in 1 quarter.
  • Paul Tudor Jones's Marinus Pharmaceuticals, Inc position peaked at $103K in Q4 2018.
  • 81 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2019.

Based on Tudor Investment Corp's 13F filing for Q1 2019, filed 15 May 2019.